MCID: ADN018
MIFTS: 59

Adenoma

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 11 75 53 14 16 71
Acinar Cell Adenoma 11 71
Adenomas 11 14
Acinic Cell Adenoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:657
MeSH 43 D000236
NCIt 49 C2855 C4196
SNOMED-CT 68 443416007 79041005
UMLS 71 C0001430 C0334389

Summaries for Adenoma

Disease Ontology: 11 A cell type benign neoplasm that is composed of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary: Adenoma, also known as acinar cell adenoma, is related to prolactinoma and parathyroid adenoma. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Dyclonine and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability

Wikipedia: 75 An adenoma is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2207)
# Related Disease Score Top Affiliating Genes
1 prolactinoma 33.2 PRL GNAS CTNNB1 CCND1 AIP
2 parathyroid adenoma 33.1 RET PRL GNAS CTNNB1 CCND1
3 pituitary adenoma 33.1 RET PRL GNAS AIP
4 pleomorphic adenoma 33.1 TP53 PLAGL2 PLAG1 CTNNB1
5 conn's syndrome 33.1 TP53 RET PRL GNAS CTNNB1 BRAF
6 growth hormone secreting pituitary adenoma 32.9 PRL GNAS AIP
7 functioning pituitary adenoma 32.9 PRL GNAS AIP
8 sebaceous adenoma 32.8 MSH6 MSH2 MLH1
9 pleomorphic adenoma carcinoma 32.8 TP53 PLAG1
10 tsh producing pituitary tumor 32.8 PRL AIP
11 colorectal adenoma 32.8 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
12 follicular adenoma 32.7 RET GNAS BRAF
13 lung adenoma 32.6 TP53 KRAS CCND1
14 villous adenoma 32.6 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
15 extrahepatic bile duct adenoma 32.4 MSH6 MSH2 MLH1
16 acidophil adenoma 32.4 PRL MSH6
17 pituitary cancer 32.4 TP53 PRL GNAS AIP
18 gastrointestinal adenoma 32.3 MSH6 MLH1 APC
19 periampullary adenoma 32.3 MSH6 APC
20 carney complex variant 32.3 TP53 RET PRL GNAS CTNNB1 AIP
21 hyperpituitarism 32.2 PRL GNAS AIP
22 parathyroid carcinoma 32.2 RET CTNNB1 CCND1 APC
23 hyperparathyroidism 2 with jaw tumors 32.2 RET CCND1
24 colon adenoma 32.2 TP53 SMAD4 SLC26A3 MLH1 KRAS CTNNB1
25 adrenal gland disease 32.0 TP53 PRL GNAS CTNNB1
26 primary hyperparathyroidism 32.0 RET PRL AIP
27 endometrial adenocarcinoma 31.9 TP53 MSH6 MSH2 MLH1 KRAS
28 juvenile polyposis syndrome 31.8 SMAD4 MSH6 MSH2 MLH1 APC
29 familial adenomatous polyposis 31.8 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
30 mixed cell type cancer 31.6 TP53 PLAG1 MLH1 KRAS CTNNB1
31 adenoid cystic carcinoma 31.6 TP53 KRAS CTNNB1 CCND1
32 multiple endocrine neoplasia, type i 31.5 RET PRL GNAS AIP
33 meningioma, familial 31.5 TP53 RET PRL CTNNB1 CCND1 APC
34 multiple endocrine neoplasia 31.5 RET PRL GNAS AIP
35 thyroid gland follicular carcinoma 31.5 TP53 RET CTNNB1 CCND1 BRAF
36 goiter 31.4 RET PRL GNAS
37 craniopharyngioma 31.4 PRL CTNNB1 BRAF APC
38 wilms tumor 1 31.3 TP53 KRAS CTNNB1 CCND1 BRAF
39 adenocarcinoma 31.3 TP53 TGFBR2 SMAD4 RET MSH6 MSH2
40 cervical adenocarcinoma 31.3 TP53 KRAS BRAF
41 thyroid gland cancer 31.2 TP53 RET KRAS CTNNB1 CCND1 BRAF
42 renal cell carcinoma, papillary, 1 31.2 TP53 RET KRAS BRAF
43 carcinosarcoma 31.2 TP53 KRAS CTNNB1
44 bladder cancer 31.2 TP53 MSH2 MLH1 KRAS CTNNB1 CCND1
45 hemangioma 31.2 TP53 RET KRAS CTNNB1
46 pituitary gland disease 31.1 PRL GNAS AIP
47 rectal benign neoplasm 31.1 TP53 MSH6 MSH2 MLH1 KRAS CTNNB1
48 thyroid tumor 31.1 RET KRAS BRAF
49 rectum cancer 31.1 TP53 MSH6 MSH2 MLH1 KRAS APC
50 mccune-albright syndrome 31.1 PRL GNAS APC AIP

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

25 (show top 50) (show all 71)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.67 MLH1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.67 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.67 THADA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.67 SMAD4 TGFBR2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.67 PLAGL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.67 TP53 TGFBR2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.67 KRAS SLC26A3 TP53
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.67 MLH1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.67 PLAGL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.67 RET
11 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.67 TP53 TGFBR2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.67 APC
13 Increased shRNA abundance (Z-score > 2) GR00366-A-134 10.67 SLC26A3 CCND1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-141 10.67 PLAGL2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.67 TGFBR2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.67 BRAF
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.67 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.67 TGFBR2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10.67 TGFBR2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.67 TP53
21 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.67 RET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.67 TP53
23 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.67 TGFBR2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-188 10.67 TGFBR2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.67 TP53
26 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.67 TP53
27 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.67 APC
28 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.67 MLH1 SMAD4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-20 10.67 TP53
30 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.67 MLH1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.67 APC
32 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.67 CCND1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.67 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.67 CCND1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.67 SMAD4
36 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.67 RET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.67 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.67 SMAD4
39 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.67 RET
40 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.67 TP53
41 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.67 CCND1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.67 TP53 TGFBR2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.67 THADA
44 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.67 SMAD4
45 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.67 BRAF CTNNB1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-48 10.67 TGFBR2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.67 RET
48 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.67 SLC26A3
49 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.67 RET TGFBR2
50 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10.67 TP53

MGI Mouse Phenotypes related to Adenoma:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.53 AIP APC BRAF CCND1 CTNNB1 GNAS
2 neoplasm MP:0002006 10.5 AIP APC BRAF CCND1 CTNNB1 GNAS
3 growth/size/body region MP:0005378 10.46 AIP APC AXIN2 BRAF CCND1 CTNNB1
4 endocrine/exocrine gland MP:0005379 10.45 AIP APC AXIN2 BRAF CCND1 CTNNB1
5 nervous system MP:0003631 10.42 APC AXIN2 BRAF CCND1 CTNNB1 GNAS
6 normal MP:0002873 10.4 APC AXIN2 BRAF CCND1 CTNNB1 GNAS
7 digestive/alimentary MP:0005381 10.4 APC AXIN2 BRAF CCND1 CTNNB1 GNAS
8 cellular MP:0005384 10.4 AIP APC AXIN2 BRAF CCND1 CTNNB1
9 embryo MP:0005380 10.31 AIP APC AXIN2 BRAF CTNNB1 GNAS
10 immune system MP:0005387 10.31 APC BRAF CCND1 CTNNB1 GNAS KRAS
11 liver/biliary system MP:0005370 10.29 AIP APC BRAF CTNNB1 GNAS KRAS
12 limbs/digits/tail MP:0005371 10.28 APC AXIN2 BRAF CTNNB1 GNAS KRAS
13 behavior/neurological MP:0005386 10.27 APC AXIN2 BRAF CCND1 CTNNB1 GNAS
14 renal/urinary system MP:0005367 10.26 APC BRAF CTNNB1 GNAS KRAS RET
15 cardiovascular system MP:0005385 10.26 AIP APC AXIN2 BRAF CCND1 CTNNB1
16 muscle MP:0005369 10.25 APC BRAF CTNNB1 GNAS KRAS RET
17 craniofacial MP:0005382 10.25 APC AXIN2 BRAF CCND1 CTNNB1 GNAS
18 reproductive system MP:0005389 10.18 APC AXIN2 BRAF CCND1 CTNNB1 KRAS
19 hearing/vestibular/ear MP:0005377 10.11 APC BRAF CTNNB1 GNAS KRAS PLAG1
20 pigmentation MP:0001186 10.1 APC BRAF CTNNB1 KRAS TGFBR2 TP53
21 respiratory system MP:0005388 10.06 BRAF CCND1 CTNNB1 GNAS KRAS MLH1
22 skeleton MP:0005390 10.06 APC AXIN2 BRAF CCND1 CTNNB1 GNAS
23 hematopoietic system MP:0005397 10.03 APC BRAF CCND1 CTNNB1 GNAS KRAS
24 vision/eye MP:0005391 9.96 APC AXIN2 BRAF CCND1 CTNNB1 GNAS
25 mortality/aging MP:0010768 9.89 AIP APC AXIN2 BRAF CCND1 CTNNB1
26 integument MP:0010771 9.5 AIP APC AXIN2 BRAF CCND1 CTNNB1

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dyclonine Approved Phase 4 586-60-7 3180
2
Scopolamine Approved, Investigational Phase 4 51-34-3 153311 3000322
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
4
Simethicone Approved Phase 4 8050-81-5
5
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
6
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
9
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
10
Codeine Approved, Illicit Phase 4 76-57-3, 6854-40-6 5284371 5362471
11
Sunitinib Approved, Investigational Phase 4 557795-19-4 5329102
12
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
13
Nutmeg Approved Phase 4
14
Cefuroxime Approved Phase 4 55268-75-2 5479529
15
Cefdinir Approved Phase 4 91832-40-5 6915944
16
Cefazolin Approved Phase 4 25953-19-9 33255
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Sulfamethoxazole Approved Phase 4 723-46-6 5329
19
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
20
Cabergoline Approved Phase 4 81409-90-7 54746
21
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
22
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
23
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
24
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
25
Lactitol Approved, Investigational Phase 4 585-86-4 157355
26
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
27
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
28 Parasympatholytics Phase 4
29 Anticonvulsants Phase 4
30 Bromides Phase 4
31 Butylscopolammonium Bromide Phase 4
32 Muscarinic Antagonists Phase 4
33 Cholinergic Antagonists Phase 4
34 Cholinergic Agents Phase 4
35 Angiogenesis Inhibitors Phase 4
36 Proton Pump Inhibitors Phase 4
37 Emollients Phase 4
38 Insulin, Globin Zinc Phase 4
39
Insulin Phase 4
40 Cathartics Phase 4
41 Laxatives Phase 4
42 Polyethylene glycol 3350 Phase 4
43 HIV Protease Inhibitors Phase 4
44
protease inhibitors Phase 4
45 Analgesics, Opioid Phase 4
46 Narcotics Phase 4
47 Antitussive Agents Phase 4
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
49
Sitagliptin Phosphate Phase 4 654671-77-9
50 Dipeptidyl-Peptidase IV Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 771)
# Name Status NCT ID Phase Drugs
1 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Unknown status NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
2 Comparison of the Efficacy and Tolerability Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Unknown status NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
3 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Unknown status NCT02832869 Phase 4
4 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
5 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
6 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
7 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
8 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Completed NCT02638584 Phase 4 Ilaprazole;Rabeprazole
9 The Effect Of Adding High Dose Simethicone To A Standard Polyethylene Glycol Preparation On Adenoma Detection Rate During Screening Colonoscopy: A Randomized Controlled Pilot Trial Completed NCT03119168 Phase 4 Simethicone Solution
10 Can Involvement of Endoscopy Nurse Participation Increase Adenoma Detection Rate During Screening Colonoscopy?:A Prospective Multicenter Randomized Trial Completed NCT01124266 Phase 4
11 A Multicentre Randomized Parallel Group Phase IV Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Completed NCT03742232 Phase 4 PEG3350;Macrogol 4000
12 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study Completed NCT02507037 Phase 4 polyethylene glycol
13 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
14 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Completed NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
15 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
16 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
17 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
18 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
19 An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women Recruiting NCT05038878 Phase 4 Elagolix
20 Comparison Between a 1L of Polyethylene Glycol+Ascorbic Acid as a Split Dose Bowel Preparation for Colonoscopy: Prospective, Randomized, Parallel, Multi-center Trial Recruiting NCT04758156 Phase 4 CleanViewAL;SUPREP
21 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
22 Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China. Active, not recruiting NCT02842749 Phase 4 everolimus
23 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline
24 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Suspended NCT01023984 Phase 4
25 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Terminated NCT02032784 Phase 4 octreotide
26 Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas Terminated NCT00720902 Phase 4 growth hormone releasing hormone (GHRH) & arginine
27 GRAND BLEU Study: Does the Colonoscopy With Instillation of Blue Water (Indigo Carmin® Dilute) Enable an Improved Rate of Adenoma Detection for Colonoscopy With Insufflation of Air? Unknown status NCT01937429 Phase 3
28 Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial Unknown status NCT02143505 Phase 2, Phase 3 Ca plus vit D
29 Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection Unknown status NCT01157598 Phase 3
30 Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
31 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
32 Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy Completed NCT01411189 Phase 3 Menthol
33 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
34 Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study Completed NCT00002527 Phase 3 aspirin
35 Comparison of a Split Dose Bowel Preparation With 2-L Polyethylene Glycol Plus Ascorbic Acid and 1-L Polyethylene Glycol Plus Ascorbic Acid and Bisacodyl Prior to Colonoscopy Completed NCT02980562 Phase 3 Polyethylene Glycols;Bisacodyl
36 A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy Completed NCT02250196 Phase 3 PEG-Asc;SPMC 2
37 Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Completed NCT03027557 Phase 3 Cinacalcet 30 mg Tablet;Denosumab Inj 60 mg/ml
38 Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) Completed NCT00141193 Phase 3 Celecoxib
39 Polyp Prevention Trial Completed NCT00339625 Phase 3
40 A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas Completed NCT00282386 Phase 3 MK0966; Rofecoxib / Duration of Treatment: 156 weeks;Placebo/ Duration of Treatment: 156 weeks
41 A Prospective Comparative Study of Papillectomy Completed NCT02165852 Phase 3
42 A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas Completed NCT02226185 Phase 2, Phase 3 Berberine hydrochloride;placebo
43 A Randomized Prospective Trial Comparing Different Regimens of Polyethylene Glycol-based Lavage and Sodium Picosulphate With Magnesium Citrate in the Preparation of Patients for Colonoscopy Completed NCT01778192 Phase 3 Polyethylene glycol;Sodium picosulphate with magnesium citrate
44 The Effect of Berberine Hydrochloride in Familial Adenomatous Polyposis:a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial Completed NCT03333265 Phase 2, Phase 3 100mg Berberine hydrochloride;300mg Berberine hydrochloride;Placebo Oral Tablet
45 A Randomized Trial of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer Completed NCT03281096 Phase 2, Phase 3 Berberine hydrochloride;Placebo
46 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Completed NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
47 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
48 18F-Fluorocholine for the Detection of Parathyroid Adenomas Completed NCT03764007 Phase 2, Phase 3 18F-Fluorocholine
49 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
50 Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Octreotide
Octreotide Acetate

Genetic Tests for Adenoma

Anatomical Context for Adenoma

Organs/tissues related to Adenoma:

MalaCards : Pituitary, Thyroid, Prostate, Colon, Salivary Gland, Liver, Pancreas

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 52851)
# Title Authors PMID Year
1
Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. 53 62
20514431 2010
2
Biallelic MYH germline mutations as cause of Muir-Torre syndrome. 53 62
19998059 2010
3
Wnt signaling may be activated in a subset of Peutz-Jeghers syndrome polyps closely correlating to LKB1 expression. 53 62
20428811 2010
4
The safety and efficacy of celecoxib in children with familial adenomatous polyposis. 53 62
20234350 2010
5
Nuclear or cytoplasmic localization of Bag-1 distinctly correlates with pathologic behavior and outcome of gastric carcinomas. 53 62
20096920 2010
6
Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. 53 62
20196079 2010
7
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. 53 62
20107900 2010
8
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas. 53 62
20503447 2010
9
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. 53 62
20427397 2010
10
Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. 53 62
20195621 2010
11
ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. 53 62
20307197 2010
12
Adrenocortical zonation in humans under normal and pathological conditions. 53 62
20200334 2010
13
The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. 53 62
20335450 2010
14
KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. 53 62
20305537 2010
15
Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in cushing adenoma. 53 62
19894022 2010
16
Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. 53 62
20060152 2010
17
Chemoprophylaxis in gastrointestinal tumors. 53 62
20496537 2010
18
Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients. 53 62
20332274 2010
19
REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. 53 62
20183800 2010
20
Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. 53 62
20459557 2010
21
Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. 53 62
20111911 2010
22
Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. 53 62
20208994 2010
23
High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. 53 62
20145615 2010
24
Complete deletion of Apc results in severe polyposis in mice. 53 62
20010873 2010
25
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. 53 62
20233436 2010
26
Identification of histologically distinct conventional adenomas that arise predominately in patients with sessile serrated adenomas. 53 62
20118768 2010
27
Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. 53 62
19755524 2010
28
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 53 62
20106827 2010
29
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. 53 62
19965918 2010
30
Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. 53 62
20145122 2010
31
The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. 53 62
20093774 2010
32
Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. 53 62
20086108 2010
33
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. 53 62
20087348 2010
34
O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report. 53 62
20087113 2010
35
Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. 53 62
19855374 2010
36
Identifying mutations for MYH-associated polyposis. 53 62
20063264 2010
37
Molecular genetics of hepatocellular neoplasia. 53 62
20182587 2010
38
Gradual loss of functional gap junction within progression of colorectal cancer -- a shift from membranous CX32 and CX43 expression to cytoplasmic pattern during colorectal carcinogenesis. 53 62
20133984 2010
39
CT-MIBI-SPECT image fusion predicts multiglandular disease in hyperparathyroidism. 53 62
19705144 2010
40
Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. 53 62
20150876 2010
41
ACTH-independent Cushing's syndrome with bilateral micronodular adrenal hyperplasia and ectopic adrenocortical adenoma. 53 62
19915020 2010
42
Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas. 53 62
19526345 2010
43
HERG1 gene expression as a specific tumor marker in colorectal tissues. 53 62
19577877 2010
44
[Differentiated therapy of liver tumors]. 53 62
20062959 2010
45
Synaptophysin immunoreactivity in adrenocortical adenomas: a correlation between synaptophysin and CYP17A1 expression. 53 62
19755404 2009
46
A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation. 53 62
19955943 2009
47
An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1. 53 62
19253033 2009
48
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. 53 62
20046424 2009
49
Clear cell change in colonic polyps. 53 62
18611940 2009
50
Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. 53 62
19864471 2009

Variations for Adenoma

Expression for Adenoma

Search GEO for disease gene expression data for Adenoma.

Pathways for Adenoma

Pathways related to Adenoma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 TP53 TGFBR2 SMAD4 KRAS GNAS CTNNB1
2 13.69 APC AXIN2 BRAF CCND1 CTNNB1 GNAS
3
Show member pathways
13.65 APC BRAF CCND1 CTNNB1 GNAS KRAS
4
Show member pathways
13.39 TP53 PRL MSH6 KRAS GNAS CTNNB1
5
Show member pathways
13.34 APC BRAF CTNNB1 KRAS RET SMAD4
6
Show member pathways
12.82 KRAS CTNNB1 BRAF AXIN2 APC
7
Show member pathways
12.81 TP53 TGFBR2 SMAD4 KRAS CCND1 BRAF
8
Show member pathways
12.8 TP53 TGFBR2 SMAD4 AXIN2 APC
9
Show member pathways
12.79 TP53 CTNNB1 CCND1 AXIN2 APC
10 12.48 TP53 MSH6 MSH2 MLH1 CCND1
11
Show member pathways
12.47 TP53 KRAS CTNNB1 BRAF
12
Show member pathways
12.44 TP53 CTNNB1 CCND1 BRAF
13
Show member pathways
12.42 TP53 TGFBR2 KRAS CTNNB1
14
Show member pathways
12.42 TGFBR2 SMAD4 GNAS CTNNB1 APC
15 12.38 TP53 GNAS CTNNB1 CCND1 APC
16 12.37 TP53 TGFBR2 KRAS BRAF
17
Show member pathways
12.35 TP53 TGFBR2 SMAD4 MSH6 MSH2 MLH1
18
Show member pathways
12.29 TP53 SMAD4 KRAS CTNNB1 CCND1 BRAF
19 12.21 SMAD4 CTNNB1 AXIN2 APC
20
Show member pathways
12.2 TP53 KRAS CCND1 BRAF
21 12.1 TP53 TGFBR2 SMAD4 KRAS CTNNB1
22 12.03 TP53 MSH2 MLH1 APC
23 12.02 TP53 KRAS BRAF AXIN2 APC
24 11.99 BRAF CCND1 CTNNB1 KRAS MSH2 MSH6
25
Show member pathways
11.86 CTNNB1 CCND1 APC
26 11.85 GNAS CTNNB1 BRAF
27 11.85 TP53 SMAD4 KRAS CTNNB1 CCND1 APC
28 11.84 TGFBR2 SMAD4 KRAS BRAF
29 11.82 TP53 MSH6 CCND1
30
Show member pathways
11.8 TP53 MSH6 MSH2
31 11.78 MLH1 MSH2 TP53
32
Show member pathways
11.77 RET KRAS BRAF
33
Show member pathways
11.77 TP53 TGFBR2 KRAS
34 11.76 TP53 KRAS BRAF
35 11.7 SMAD4 CTNNB1 APC
36 11.68 TP53 CTNNB1 CCND1
37 11.68 CTNNB1 SMAD4 TGFBR2 TP53
38 11.68 CTNNB1 CCND1 AXIN2 APC
39 11.66 TP53 TGFBR2 SMAD4 KRAS CTNNB1 CCND1
40 11.65 TP53 TGFBR2 SMAD4 MSH6 MSH2 MLH1
41
Show member pathways
11.62 KRAS GNAS BRAF
42 11.62 SMAD4 PRL CCND1 AXIN2
43
Show member pathways
11.59 TP53 CCND1 APC
44 11.57 TP53 SMAD4 CCND1
45 11.51 TGFBR2 SMAD4 CTNNB1
46 11.47 CTNNB1 CCND1 APC
47
Show member pathways
11.41 TP53 MSH2 MLH1
48 11.38 TP53 MSH6 MSH2
49 11.36 TP53 KRAS CCND1 BRAF
50
Show member pathways
11.24 APC AXIN2 CTNNB1

GO Terms for Adenoma

Cellular components related to Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 9.33 MSH2 MLH1
2 MutSalpha complex GO:0032301 9.26 MSH6 MSH2
3 beta-catenin destruction complex GO:0030877 9.1 CTNNB1 AXIN2 APC

Biological processes related to Adenoma according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.41 BRAF CTNNB1 KRAS PLAG1 RET TP53
2 negative regulation of cell population proliferation GO:0008285 10.32 TP53 TGFBR2 SMAD4 CTNNB1 AXIN2 APC
3 response to xenobiotic stimulus GO:0009410 10.26 TP53 TGFBR2 RET CTNNB1 CCND1
4 in utero embryonic development GO:0001701 10.26 TP53 TGFBR2 SMAD4 MSH2 CTNNB1
5 negative regulation of neuron apoptotic process GO:0043524 10.23 MSH2 KRAS CCND1 BRAF
6 cellular response to DNA damage stimulus GO:0006974 10.23 TP53 MSH6 MSH2 MLH1 CCND1 APC
7 MAPK cascade GO:0000165 10.22 BRAF CTNNB1 KRAS RET
8 positive regulation of miRNA transcription GO:1902895 10.11 TP53 SMAD4 PRL
9 T cell differentiation in thymus GO:0033077 10.09 TP53 CTNNB1 BRAF
10 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 10.04 MSH6 MSH2 MLH1
11 mismatch repair GO:0006298 10.02 MSH6 MSH2 MLH1
12 regulation of cell population proliferation GO:0042127 10 TP53 TGFBR2 SMAD4 CTNNB1 BRAF
13 gastrulation GO:0007369 9.97 SMAD4 TGFBR2 TP53
14 determination of adult lifespan GO:0008340 9.97 TP53 MSH6 MSH2
15 DNA-templated transcription GO:0006351 9.97 SMAD4 PLAGL2 PLAG1 CTNNB1 AIP
16 response to X-ray GO:0010165 9.95 TP53 MSH2 CCND1
17 trachea formation GO:0060440 9.94 TGFBR2 CTNNB1
18 positive regulation of helicase activity GO:0051096 9.92 MSH6 MSH2
19 isotype switching GO:0045190 9.91 MLH1 MSH2 MSH6
20 positive regulation of isotype switching to IgA isotypes GO:0048298 9.9 MLH1 MSH2
21 positive regulation of epithelial to mesenchymal transition GO:0010718 9.86 AXIN2 CTNNB1 SMAD4 TGFBR2
22 regulation of centromeric sister chromatid cohesion GO:0070602 9.84 CTNNB1 AXIN2
23 response to steroid hormone GO:0048545 9.81 AXIN2 CCND1 TGFBR2
24 somatic hypermutation of immunoglobulin genes GO:0016446 9.8 MSH6 MSH2 MLH1
25 hair follicle placode formation GO:0060789 9.77 CTNNB1 GNAS
26 cell population proliferation GO:0008283 9.7 TP53 SMAD4 KRAS CTNNB1 CCND1 AXIN2
27 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.58 MSH2 MLH1
28 trachea morphogenesis GO:0060439 9.52 TGFBR2 CTNNB1
29 maintenance of DNA repeat elements GO:0043570 9.35 MSH6 MSH2 AXIN2
30 somatic recombination of immunoglobulin gene segments GO:0016447 9.02 MSH6 MSH2 MLH1

Molecular functions related to Adenoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 10.26 TP53 MSH2 CTNNB1 CCND1 AXIN2 APC
2 chromatin binding GO:0003682 10.23 CTNNB1 MLH1 MSH2 MSH6 SMAD4 TP53
3 nucleotide binding GO:0000166 10.03 TGFBR2 RET MSH6 MSH2 MLH1 KRAS
4 enzyme binding GO:0019899 10 AXIN2 CCND1 CTNNB1 MLH1 MSH2 MSH6
5 MutLalpha complex binding GO:0032405 9.81 MSH6 MSH2
6 oxidized purine DNA binding GO:0032357 9.8 MSH6 MSH2
7 ATP-dependent DNA damage sensor activity GO:0140664 9.8 MSH6 MSH2 MLH1
8 I-SMAD binding GO:0070411 9.73 SMAD4 CTNNB1 AXIN2
9 single guanine insertion binding GO:0032142 9.71 MSH2 MSH6
10 single thymine insertion binding GO:0032143 9.67 MSH6 MSH2
11 mismatched DNA binding GO:0030983 9.35 MSH6 MSH2 MLH1
12 guanine/thymine mispair binding GO:0032137 9.1 MSH6 MSH2 MLH1

Sources for Adenoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....